GlassScriptPhysician profile
Youssef Nejjar
NPI 1689834459
$8,334.86
in general payments reported to CMS, 2019-2025
62 companies · $1,642 in 2025
The $1,642 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $916 · 2021: $1,047 · 2022: $1,116 · 2023: $1,280 · 2024: $1,274 · 2025: $1,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $936.03 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $559.25 | 2019-2025 | |
| Lilly USA, LLC | $468.98 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Amgen INC. | $452.48 | 2019-2025 | Aimovig, Uplizna |
| Pfizer INC. | $440.94 | 2022-2025 | |
| Ucb, INC. | $418.50 | 2019-2025 | Nayzilam, Briviact |
| Eisai INC. | $325.74 | 2019-2025 | |
| Lundbeck LLC | $320.71 | 2021-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $259.14 | 2020-2025 | Valtoco |
| Neurocrine Biosciences, INC. | $217.22 | 2022-2025 | Ingrezza, Ongentys |
| Genzyme Corporation | $186.46 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $185.62 | 2019-2025 | Ajovy, Austedo Xr |
| Amneal Pharmaceuticals LLC | $168.24 | 2021-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Alexion Pharmaceuticals, INC. | $166.42 | 2019-2025 | Ultomiris |
| Biogen, INC. | $162.64 | 2019-2024 | Skyclarys, Vumerity, Tysabri |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Nejjar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.